278: Illumina, Grail and FTC scrutiny of vertical mergers in human genetic technologies

Rashid AI et al., The American Journal of Human Genetics, Corrected proof. doi:10.1016/j.ajhg.2025.12.012 - US antitrust shifts in human genetic technologies: FTC scrutiny of Illumina’s acquisition of Grail alters NGS market oversight and could affect spin-offs and startups. Key terms: Illumina, Grail, vertical mergers, FTC merger guidelines, non-compete rule. Study Highlights:This perspective examines the US legal and regulatory landscape for human genetic and genomic technologies, focusing on FTC and DOJ policy changes and enforcement habits. Using a case-study approach centered on Illumina’s proposed acquisition and eventual divestiture of Grail, the authors review updated merger guidelines, non-compete rule developments, and exclusive-dealing concerns. They report that the 2023 merger guidelines lowered thresholds for presumed anti-competitiveness and that the FTC’s challenge emphasized risks to nascent mult-cancer early detection competitors that rely on next-generation sequencing platforms. The authors conclude that heightened vertical-merger scrutiny may reduce spin-offs and early-stage acquisitions, prompting firms to favor in-house R&D or alternate collaboration models. Conclusion:Heightened scrutiny of vertical mergers and attention to nascent competition in US antitrust policy is likely to reshape biotechnology strategies by reducing spin-offs and encouraging in-house development. Music:Enjoy the music based on this article at the end of the episode. Article title:Competition in human genetic technologies: The current US legal landscape First author:Rashid AI Journal:The American Journal of Human Genetics, Corrected proof. doi:10.1016/j.ajhg.2025.12.012 DOI:10.1016/j.ajhg.2025.12.012 Reference:Rashid AI, Rincon NA, Rihani N, Wagner JK. Competition in human genetic technologies: The current US legal landscape. The American Journal of Human Genetics. 2026;113:1–10. https://doi.org/10.1016/j.ajhg.2025.12.012 License:This episode is based on an open-access article published under the Creative Commons Attribution 4.0 International License (CC BY 4.0) - https://creativecommons.org/licenses/by/4.0/ Support:Base by Base – Stripe donations: https://donate.stripe.com/7sY4gz71B2sN3RWac5gEg00 Official website https://basebybase.com On PaperCast Base by Base you’ll discover the latest in genomics, functional genomics, structural genomics, and proteomics. Episode link: https://basebybase.com/episodes/illumina-grail-vertical-mergers QC:This episode was checked against the original article PDF and publication metadata for the episode release published on 2026-02-02. QC Scope:- article metadata and core scientific claims from the narration- excludes analogies, intro/outro, and music- transcript coverage: Audited the transcript sections that discuss antitrust policy landscape, the Illumina/Grail vertical merger case, regulatory instruments (HSR, Sherman, Clayton), NASCENT competition, spin-offs and IRS spin-off rules, non-compete status, and startup financing implications.- transcript topics: Illumina/Grail vertical merger case; Foreclosure theory in vertical mergers; Open offer and divestiture outcome; 2023 merger guidelines and vertical mergers; Nascent competition and spin-offs; IRS rules on corporate spin-offs QC Summary:- factual score: 10/10- metadata score: 10/10- supported core claims: 8- claims flagged for review: 0- metadata checks passed: 4- metadata issues found: 0 Metadata Audited:- article_doi- article_title- article_journal- license Factual Items Audited:- Illumina/Grail case as a vertical merger example with divestiture- Foreclosure as a potential anti-competitive mechanism in vertical mergers- 2023 merger gu...